JP2011517318A5 - - Google Patents

Download PDF

Info

Publication number
JP2011517318A5
JP2011517318A5 JP2010549679A JP2010549679A JP2011517318A5 JP 2011517318 A5 JP2011517318 A5 JP 2011517318A5 JP 2010549679 A JP2010549679 A JP 2010549679A JP 2010549679 A JP2010549679 A JP 2010549679A JP 2011517318 A5 JP2011517318 A5 JP 2011517318A5
Authority
JP
Japan
Prior art keywords
cathepsin
mmp
amde
adamts
activator
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010549679A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011517318A (ja
JP5709531B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/001486 external-priority patent/WO2009111083A2/en
Publication of JP2011517318A publication Critical patent/JP2011517318A/ja
Publication of JP2011517318A5 publication Critical patent/JP2011517318A5/ja
Application granted granted Critical
Publication of JP5709531B2 publication Critical patent/JP5709531B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010549679A 2008-03-06 2009-03-06 可活性化型マトリックス分解酵素の生体内一時的制御 Expired - Fee Related JP5709531B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US6866708P 2008-03-06 2008-03-06
US61/068,667 2008-03-06
US12772508P 2008-05-14 2008-05-14
US61/127,725 2008-05-14
PCT/US2009/001486 WO2009111083A2 (en) 2008-03-06 2009-03-06 In vivo temporal control of activ at able matrix- degrading enzymes

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013207338A Division JP2014043449A (ja) 2008-03-06 2013-10-02 可活性化型マトリックス分解酵素の生体内一時的制御

Publications (3)

Publication Number Publication Date
JP2011517318A JP2011517318A (ja) 2011-06-02
JP2011517318A5 true JP2011517318A5 (https=) 2011-09-22
JP5709531B2 JP5709531B2 (ja) 2015-04-30

Family

ID=41017153

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2010549679A Expired - Fee Related JP5709531B2 (ja) 2008-03-06 2009-03-06 可活性化型マトリックス分解酵素の生体内一時的制御
JP2013207338A Pending JP2014043449A (ja) 2008-03-06 2013-10-02 可活性化型マトリックス分解酵素の生体内一時的制御

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2013207338A Pending JP2014043449A (ja) 2008-03-06 2013-10-02 可活性化型マトリックス分解酵素の生体内一時的制御

Country Status (15)

Country Link
US (2) US9833498B2 (https=)
EP (1) EP2274004B1 (https=)
JP (2) JP5709531B2 (https=)
KR (3) KR20100135779A (https=)
AR (1) AR076627A1 (https=)
AU (1) AU2009220094B2 (https=)
BR (1) BRPI0909622A2 (https=)
CA (1) CA2718549C (https=)
CL (2) CL2009000541A1 (https=)
CO (1) CO6331294A2 (https=)
ES (1) ES2586765T3 (https=)
IL (1) IL207293A (https=)
MX (1) MX2010009806A (https=)
TW (1) TWI395593B (https=)
WO (1) WO2009111083A2 (https=)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2508948A1 (en) 2002-12-16 2004-07-15 Halozyme, Inc. Human chondroitinase glycoprotein (chasegp), process for preparing the same, and pharmaceutical compositions comprising thereof
US20090123367A1 (en) * 2003-03-05 2009-05-14 Delfmems Soluble Glycosaminoglycanases and Methods of Preparing and Using Soluble Glycosaminoglycanases
NZ542873A (en) 2003-03-05 2008-07-31 Halozyme Inc Soluble, neutral-active hyaluronidase activity glycoprotein (sHASEGP) that is produced with high yield in a mammalian expression system by introducing nucleic acids that lack a narrow region encoding amino acids in the carboxy terminus of the human PH20 cDNA
US7871607B2 (en) * 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
TWI395593B (zh) 2008-03-06 2013-05-11 Halozyme Inc 可活化的基質降解酵素之活體內暫時性控制
TWI489994B (zh) 2008-03-17 2015-07-01 Baxter Healthcare Sa 供免疫球蛋白及玻尿酸酶之皮下投藥之用的組合及方法
KR20130116386A (ko) * 2008-04-14 2013-10-23 할로자임, 아이엔씨 히알루로난 관련 질환 및 상태 치료용 변형된 히알루로니다제 및 그 용도
TWI394580B (zh) * 2008-04-28 2013-05-01 Halozyme Inc 超快起作用胰島素組成物
EA022752B1 (ru) * 2008-12-09 2016-02-29 Галозим, Инк. Длинные растворимые полипептиды рн20 и их использование
EP2403523A1 (en) * 2009-03-06 2012-01-11 Halozyme, Inc. Temperature sensitive mutants of matrix metalloprotease 1 und uses thereof
NZ604050A (en) 2010-06-11 2014-10-31 Dvo Inc Nutrient recovery systems and methods
WO2012012300A2 (en) 2010-07-20 2012-01-26 Halozyme, Inc. Adverse side-effects associated with administration of an anti-hyaluronan agent and methods for ameliorating or preventing the side-effects
MX349622B (es) 2010-09-08 2017-08-07 Halozyme Inc Metodos para evaluar e identificar o evolucionar proteinas terapeuticas condicionalmente activas.
WO2012048291A2 (en) * 2010-10-08 2012-04-12 Proteapex Therapeutics Llc Compositions and methods for inhibition of mmp:mmp-substrate interactions
US9414930B2 (en) 2010-10-26 2016-08-16 Kyphon SÀRL Activatable devices containing a chemonucleolysis agent
US8404268B2 (en) 2010-10-26 2013-03-26 Kyphon Sarl Locally targeted anti-fibrotic agents and methods of use
US8740982B2 (en) 2010-10-26 2014-06-03 Kyphon Sarl Devices containing a chemonucleolysis agent and methods for treating an intervertebral disc or spinal arachnoiditis
WO2012155212A1 (en) * 2011-05-18 2012-11-22 David Chin Method of treating excessive collagen formation
JP5860651B2 (ja) * 2011-09-30 2016-02-16 オリンパス株式会社 ホタル由来ルシフェラーゼ
FR2984130A1 (fr) * 2011-12-14 2013-06-21 Oreal Utilisation de la proteine mmp-12 dans la prevention et/ou le traitement des peaux vieillies ou senescentes.
FR2984127A1 (fr) * 2011-12-14 2013-06-21 Oreal Utilisation de la proteine mmp-12 dans la prevention et/ou le traitement des peaux grasses et/ou a tendance grasse.
FR2984128A1 (fr) * 2011-12-14 2013-06-21 Oreal Utilisation de la proteine mmp-12 dans la prevention et/ou le traitement des peaux sensibles.
FR2984129B1 (fr) * 2011-12-14 2014-01-10 Oreal Utilisation de la proteine mmp-12 dans la prevention et/ou le traitement des etats pelliculaires du cuir chevelu
CN108686203A (zh) 2012-04-04 2018-10-23 哈洛齐梅公司 使用抗透明质酸剂和肿瘤靶向紫杉烷的组合疗法
EP2852403B1 (en) 2012-04-30 2018-03-07 Elastomics AB Methods for modification of tissues
WO2014107745A1 (en) * 2013-01-07 2014-07-10 Halozyme, Inc. Metal sensitive mutants of matrix metalloproteases and uses thereof
WO2014172526A1 (en) * 2013-04-18 2014-10-23 Drexel University Novel methods of use of biomimetic proteoglycans
CA2920835A1 (en) 2013-08-20 2015-02-26 Anutra Medical, Inc. Syringe fill system and method
EP3052095A4 (en) * 2013-10-03 2017-07-05 Imprimis Pharmaceuticals Inc. Epinephrine-based ophthalmic compositions for intraocular administration and methods for fabricating thereof
FI127924B (en) * 2014-02-27 2019-05-31 Oy Medix Biochemica Ab METHOD OF MEASURING MMP-8 ACTIVATION
USD763433S1 (en) 2014-06-06 2016-08-09 Anutra Medical, Inc. Delivery system cassette
USD750768S1 (en) 2014-06-06 2016-03-01 Anutra Medical, Inc. Fluid administration syringe
USD774182S1 (en) 2014-06-06 2016-12-13 Anutra Medical, Inc. Anesthetic delivery device
LT3388075T (lt) 2015-03-27 2023-11-10 Immatics Biotechnologies Gmbh Nauji peptidai ir peptidų deriniai, skirti naudoti imunoterapijai prieš įvairius navikus (seq id 25 - mrax5-003)
GB201505305D0 (en) 2015-03-27 2015-05-13 Immatics Biotechnologies Gmbh Novel Peptides and combination of peptides for use in immunotherapy against various tumors
US10493247B2 (en) 2016-03-15 2019-12-03 Medtronic Holding Company Sàrl Devices for delivering a chemical denervation agent and methods of use
EP3503873A4 (en) 2016-08-25 2020-04-15 Harrow IP, LLC EPINEPHRINE-BASED OPHTHALMIC COMPOSITIONS FOR INTRAOCULAR ADMINISTRATION AND METHOD FOR THE PRODUCTION THEREOF
US10758559B1 (en) 2017-09-01 2020-09-01 University Of Wyoming Targeting cathepsin K to facilitate wound healing
US11766467B2 (en) 2017-09-01 2023-09-26 University Of Wyoming Methods of treating wounds using cathepsin K inhibitors
WO2019182745A1 (en) 2018-03-19 2019-09-26 Bryn Pharma, LLC Epinephrine spray formulations
AU2019271132B2 (en) * 2018-05-15 2026-02-05 Translate Bio, Inc. Subcutaneous delivery of messenger RNA
EP3931330A4 (en) 2019-02-25 2023-03-15 Ginkgo Bioworks, Inc. BIOSYNTHESIS OF CANNABINOIDS AND CANNABINOID PRECURSORS
JP7316647B2 (ja) * 2019-07-16 2023-07-28 日本メナード化粧品株式会社 カテプシンｖ活性促進剤及びｇａｔａ－３産生抑制剤
MX2022003768A (es) * 2019-10-03 2022-08-19 Vitruvia Holdings Inc Metodo de restauracion del tejido conectivo.
US20230190881A1 (en) 2020-02-17 2023-06-22 Biotest Ag Subcutaneous administration of factor viii
CN115702242A (zh) * 2020-04-20 2023-02-14 医药控股公司 一种改性的细菌透明质酸酶多肽、生产方法、药物组合物及其用途
US11370973B2 (en) 2020-07-10 2022-06-28 Saudi Arabian Oil Company Processes and systems for producing one or more of benzene, toluene, or mixed xylenes
KR102486046B1 (ko) 2020-12-14 2023-01-11 주식회사 뉴온바이오 근육질환, 비만 또는 당뇨병 치료, 또는 예방용 조성물
TW202308689A (zh) * 2021-04-21 2023-03-01 美商健生生物科技公司 高濃度的雙特異性抗體調配物
GB2607584B (en) * 2021-06-03 2024-07-17 Stichting Medische Kliniek Velsen Composition and method of treatment
CN115786302A (zh) * 2022-12-28 2023-03-14 无锡蔚蓝生物科技有限公司 脂肪酶突变体及其在白酒黄水处理中的应用

Family Cites Families (153)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3539794A (en) 1967-09-12 1970-11-10 American Cyanamid Co Self-contained chemiluminescent lighting device
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3630200A (en) 1969-06-09 1971-12-28 Alza Corp Ocular insert
US3710795A (en) 1970-09-29 1973-01-16 Alza Corp Drug-delivery device with stretched, rate-controlling membrane
US3847770A (en) 1972-04-10 1974-11-12 Continental Can Co Photopolymerizable compositions prepared from beta hydroxy esters and polyitaconates
US4044126A (en) 1972-04-20 1977-08-23 Allen & Hanburys Limited Steroidal aerosol compositions and process for the preparation thereof
GB1429184A (en) 1972-04-20 1976-03-24 Allen & Hanburys Ltd Physically anti-inflammatory steroids for use in aerosols
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4002531A (en) 1976-01-22 1977-01-11 Pierce Chemical Company Modifying enzymes with polyethylene glycol and product produced thereby
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
LU76148A1 (https=) 1976-11-08 1978-07-10
SU787035A1 (ru) 1978-01-11 1980-12-15 Всесоюзный научно-исследовательский и испытательный институт медицинской техники Устройство дл введени лекарственных препаратов
US4202314A (en) 1978-11-20 1980-05-13 Busygin Valery P Device for injection of medicinal preparations
JPS57128634A (en) 1981-02-03 1982-08-10 Eisai Co Ltd Elastase-containing compound increasing absorption
EP0072057B1 (en) 1981-08-10 1988-02-10 Duphar International Research B.V Automatic injection syringe
US4645668A (en) * 1983-08-04 1987-02-24 Biospecifics, Nv Method for the prevention and treatment of scars with enzymes
US4952496A (en) 1984-03-30 1990-08-28 Associated Universities, Inc. Cloning and expression of the gene for bacteriophage T7 RNA polymerase
US4769027A (en) 1984-08-15 1988-09-06 Burroughs Wellcome Co. Delivery system
US4687610A (en) 1986-04-30 1987-08-18 E. I. Du Pont De Neumours And Company Low crystallinity polyester yarn produced at ultra high spinning speeds
SE457417B (sv) 1987-04-14 1988-12-27 Astra Meditec Ab Automatisk tvaakammarspruta, foerfarande foer blandning och injicering med sprutan samt ampull foer tvaakammarspruta
GB2205643B (en) 1987-05-08 1991-03-13 Farmos Group Limited Type iii collagen degradation assay
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5122614A (en) 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US5324844A (en) 1989-04-19 1994-06-28 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
DE3921528A1 (de) 1989-06-30 1991-01-10 Draegerwerk Ag Messzelle fuer den elektrochemischen gasnachweis
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5051449A (en) 1991-02-27 1991-09-24 Kligman Albert M Treatment of cellulite with retinoids
GB9105893D0 (en) 1991-03-20 1991-05-08 Orion Yhtymae Oy Bone resorption assay based on a peptide liberated during collagen degradation
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5171081A (en) 1992-05-29 1992-12-15 Pita Joe W Chemiluminescent reactive vessel
CA2098777A1 (en) 1992-06-19 1993-12-20 Yukio Fujisawa Production of human cathepsin and its use
JPH0775573A (ja) 1992-06-19 1995-03-20 Takeda Chem Ind Ltd ヒトカテプシンの製造法および該酵素含有製剤
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
JPH06192124A (ja) 1992-12-25 1994-07-12 Toray Ind Inc 血液細胞増加剤
US5353961A (en) 1993-01-15 1994-10-11 Reseal International Limited Partnership Dual chamber dispenser
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
WO1994028024A1 (en) 1993-06-01 1994-12-08 Enzon, Inc. Carbohydrate-modified polymer conjugates with erythropoietic activity
US5354566A (en) 1993-06-02 1994-10-11 Kraft General Foods, Inc. Preparation of yeast-leavened dough crusts
GB9319103D0 (en) 1993-09-15 1993-11-03 Unilever Plc Skin care method & composition
US5395326A (en) 1993-10-20 1995-03-07 Habley Medical Technology Corporation Pharmaceutical storage and mixing syringe having high pressure assisted discharge
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5919455A (en) 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
US5446090A (en) 1993-11-12 1995-08-29 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
PT750672E (pt) 1994-03-17 2002-05-31 Max Delbrueck Centrum Sequencias de adn para metaloproteases matriciais, sua preparacao e utilizacao.
US5795569A (en) 1994-03-31 1998-08-18 Amgen Inc. Mono-pegylated proteins that stimulate megakaryocyte growth and differentiation
GEP20002180B (en) 1994-03-31 2000-07-25 Amgen Inc Composition and Methods for Stimulating Megakaryocyte Growth and Differentiation
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US6093563A (en) 1994-07-08 2000-07-25 Ibex Technologies R And D, Inc. Chondroitin lyase enzymes
US5589171A (en) 1994-08-22 1996-12-31 Advance Biofactures Of Curacao Treatment of Dupuytren's disease with collagenase
US5496284A (en) 1994-09-27 1996-03-05 Waldenburg; Ottfried Dual-chamber syringe & method
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US6544767B1 (en) * 1994-10-27 2003-04-08 Axys Pharmaceuticals, Inc. Cathespin O2 protease
DE4445969C1 (de) 1994-12-22 1996-03-14 Schott Glaswerke Spritzenzylinder für eine Zweikammer-Fertigspritze, Zweikammer-Fertigspritze und Verfahren zum Herstellen und Füllen derselben
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US5536499A (en) 1995-02-24 1996-07-16 Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. Cosmetic compositions for reducing or preventing signs of cellulite
US5523090A (en) 1995-02-24 1996-06-04 Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. Skin treatment composition
US5747027A (en) 1995-04-07 1998-05-05 The Regents Of The University Of California BH55 hyaluronidase
US6461378B1 (en) 1995-05-05 2002-10-08 Thermage, Inc. Apparatus for smoothing contour irregularities of skin surface
US5705364A (en) 1995-06-06 1998-01-06 Genentech, Inc. Mammalian cell culture process
US5672662A (en) 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
US5705170A (en) 1995-10-24 1998-01-06 Plantech International, Inc. Herbal cellulite treatments
US5747322A (en) 1996-05-09 1998-05-05 The Regents Of The University Of California Recombinant crab collagenase
US5976556A (en) 1996-06-13 1999-11-02 Active Organics, Inc. Combination of acid protease enzymes and acidic buffers and uses thereof
US5667793A (en) 1996-08-02 1997-09-16 Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. Skin care compositions for treating cellulite
US5776759A (en) 1996-09-26 1998-07-07 Incyte Pharmaceuticals, Inc. Two novel human cathepsin proteins
US6214966B1 (en) 1996-09-26 2001-04-10 Shearwater Corporation Soluble, degradable poly(ethylene glycol) derivatives for controllable release of bound molecules into solution
US6193963B1 (en) 1996-10-17 2001-02-27 The Regents Of The University Of California Method of treating tumor-bearing patients with human plasma hyaluronidase
US6258351B1 (en) 1996-11-06 2001-07-10 Shearwater Corporation Delivery of poly(ethylene glycol)-modified molecules from degradable hydrogels
US5830741A (en) 1996-12-06 1998-11-03 Boehringer Mannheim Corporation Composition for tissue dissociation containing collagenase I and II from clostridium histolyticum and a neutral protease
US6086872A (en) 1997-03-27 2000-07-11 Advance Biofactures Of Curacao, Nv Amelioration of dupuytren's disease
US6071526A (en) 1997-03-27 2000-06-06 S.W. Patentverwertungs Ges M.B. H. Cosmetic or cosmetic product for firming and soothing the skin in particular in the case of cellulite
US5990237A (en) 1997-05-21 1999-11-23 Shearwater Polymers, Inc. Poly(ethylene glycol) aldehyde hydrates and related polymers and applications in modifying amines
US6294350B1 (en) 1997-06-05 2001-09-25 Dalhousie University Methods for treating fibroproliferative diseases
EP0998572A2 (en) 1997-07-25 2000-05-10 Du Pont Pharmaceuticals Company Aggrecan degrading metallo proteases
FR2767833B1 (fr) 1997-08-29 2001-03-02 Oreal Polypeptide isole de l'epiderme et son utilisation
US5971953A (en) 1998-01-09 1999-10-26 Bachynsky; Nicholas Dual chamber syringe apparatus
US6448369B1 (en) 1997-11-06 2002-09-10 Shearwater Corporation Heterobifunctional poly(ethylene glycol) derivatives and methods for their preparation
US5985263A (en) 1997-12-19 1999-11-16 Enzon, Inc. Substantially pure histidine-linked protein polymer conjugates
US6153207A (en) 1998-03-05 2000-11-28 Pugliese; Peter T. Anti-cellulite pantyhose
JP4078032B2 (ja) 1998-03-12 2008-04-23 ネクター セラピューティックス エイエル，コーポレイション 近位の反応性基を持つポリ（エチレングリコール）誘導体
KR20010041902A (ko) 1998-03-16 2001-05-25 데이비드 엠 모이어 포유류의 피부 내의 셀룰라이트를 감소시키는 방법
US6528286B1 (en) 1998-05-29 2003-03-04 Genentech, Inc. Mammalian cell culture process for producing glycoproteins
CN1314992A (zh) 1998-07-03 2001-09-26 奈勒斯菲尔德控制有限公司 流体测量的方法和装置
US6031005A (en) 1998-08-03 2000-02-29 Easterling; W. Jerry Composition and method for treating Peyronie's disease and related connective tissue disorders
US6443914B1 (en) 1998-08-10 2002-09-03 Lysonix, Inc. Apparatus and method for preventing and treating cellulite
US6420339B1 (en) 1998-10-14 2002-07-16 Amgen Inc. Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
US6060474A (en) 1998-11-05 2000-05-09 New York Society For The Relief Of The Ruptured And Crippled Maintaining The Hospital For Special Surgery Method for preventing scar tissue formation
EP1150699A4 (en) 1999-02-01 2004-06-30 John Lezdey TREATMENT OF BLADDER AND GASTROINTESTINAL MASTO CYTOSIS
WO2000066139A2 (en) * 1999-04-29 2000-11-09 Ista Pharmaceuticals, Inc. Biochemical methods that eliminate corneal scars, opacification and haze
US6022539A (en) 1999-06-03 2000-02-08 Advance Biofactures Of Curacao Amelioration of peyronie's disease
JO2291B1 (en) 1999-07-02 2005-09-12 اف . هوفمان لاروش ايه جي Erythropoietin derivatives
CZ299516B6 (cs) 1999-07-02 2008-08-20 F. Hoffmann-La Roche Ag Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem
US6656701B2 (en) 1999-07-16 2003-12-02 Actim Organics, Inc Combination of acid protease enzymes and acidic buffers and uses thereof
US6461802B1 (en) 1999-08-02 2002-10-08 Agfa-Gevaert Adhesive layer for polyester film
AU6918700A (en) 1999-08-20 2001-03-19 Howard Murad Pharmaceutical compositions and methods for reducing the appearance of cellulite
ITMI991894A1 (it) 1999-09-09 2001-03-09 Carlo Ghisalberti Acido linoleico coniugato e trigliceride nuovi metodi di sintesi e d'uso
US6355243B1 (en) 1999-11-13 2002-03-12 Bayer Corporation Method of thrombolysis by local delivery of active plasmin
CA2394980C (en) 1999-12-22 2008-05-13 Shearwater Corporation Sterically hindered derivatives of water soluble polymers
US6413507B1 (en) 1999-12-23 2002-07-02 Shearwater Corporation Hydrolytically degradable carbamate derivatives of poly (ethylene glycol)
AU2351601A (en) 1999-12-28 2001-07-09 Asger Lau Dalmose Dual chamber syringe with a dual function piston
US20030212021A1 (en) 2001-01-25 2003-11-13 Frost Gregory I. Myeloid colony stimulating factor and uses thereof
JP2003534834A (ja) 2000-01-28 2003-11-25 ノボ ノルディスク アクティーゼルスカブ 投与量設定リミッター
US6602498B2 (en) 2000-02-22 2003-08-05 Shearwater Corporation N-maleimidyl polymer derivatives
WO2001064919A2 (en) * 2000-02-28 2001-09-07 Millennium Pharmaceuticals, Inc. 18036, a novel calpain-like protease and uses thereof
US6586398B1 (en) 2000-04-07 2003-07-01 Amgen, Inc. Chemically modified novel erythropoietin stimulating protein compositions and methods
EP1280531B1 (en) 2000-05-12 2007-01-24 Novalar Pharmaceuticals, Inc. Formulation consisting of phentolamine mesylate and the use thereof
IL152804A0 (en) 2000-05-16 2003-06-24 Bolder Biotechnology Inc Methods for refolding proteins containing free cysteine residues
US20020106388A1 (en) 2000-11-24 2002-08-08 Pugliese Peter T. Formulation of flavones and isoflavones for treatment of cellulite
EP1345628B1 (en) 2000-12-20 2011-04-13 F. Hoffmann-La Roche AG Conjugates of erythropoietin (epo) with polyethylene glycol (peg)
TWI246524B (en) 2001-01-19 2006-01-01 Shearwater Corp Multi-arm block copolymers as drug delivery vehicles
WO2002080962A1 (en) * 2001-04-06 2002-10-17 Santana Cristiano Alberto Ribe Papaine containing pharmaceutical formulation resp. its use
CA2349506C (en) 2001-06-14 2009-12-08 Duke University A method for selective expression of therapeutic genes by hyperthermia
US20030026794A1 (en) * 2001-07-31 2003-02-06 Howard Fein Selective enzyme treatment of skin conditions
US6908963B2 (en) 2001-10-09 2005-06-21 Nektar Therapeutics Al, Corporation Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith
EP1446438A2 (en) 2001-11-07 2004-08-18 Nektar Therapeutics Al, Corporation Branched polymers and their conjugates
US6972005B2 (en) 2002-05-10 2005-12-06 Boehm Jr Frank H Dual chamber syringe and dual lumen needle
US6682904B1 (en) 2002-08-15 2004-01-27 Deliatroph Pharmaceuticals, Inc. Specific inhibitors of hyaluronidase 2, and methods of identifying and using same
KR20040040782A (ko) 2002-11-08 2004-05-13 선바이오(주) 신규한 헥사-암 폴리에틸렌글리콜과 유도체 및 그의합성방법
CA2508948A1 (en) * 2002-12-16 2004-07-15 Halozyme, Inc. Human chondroitinase glycoprotein (chasegp), process for preparing the same, and pharmaceutical compositions comprising thereof
BRPI0407882B1 (pt) 2003-02-26 2021-07-27 Nektar Therapeutics Composição compreendendo conjugados de polímero-porção de fator viii e seu método de fabricação
NZ542873A (en) 2003-03-05 2008-07-31 Halozyme Inc Soluble, neutral-active hyaluronidase activity glycoprotein (sHASEGP) that is produced with high yield in a mammalian expression system by introducing nucleic acids that lack a narrow region encoding amino acids in the carboxy terminus of the human PH20 cDNA
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US20090123367A1 (en) 2003-03-05 2009-05-14 Delfmems Soluble Glycosaminoglycanases and Methods of Preparing and Using Soluble Glycosaminoglycanases
US20060104968A1 (en) * 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
US7610156B2 (en) 2003-03-31 2009-10-27 Xencor, Inc. Methods for rational pegylation of proteins
KR100512483B1 (ko) 2003-05-07 2005-09-05 선바이오(주) 신규한 폴리에틸렌글리콜-말레이미드 유도체의 합성방법
EP2644206B1 (en) 2003-05-23 2019-04-03 Nektar Therapeutics PEG derivatives containing two PEG chains
US20050042213A1 (en) 2003-08-14 2005-02-24 Insight Biopharmaceuticals Ltd. Methods and pharmaceutical compositions for modulating heparanase activation and uses thereof
US7572613B2 (en) 2004-06-25 2009-08-11 Klein Jeffrey A Drug delivery system for accelerated subcutaneous absorption
US7854929B2 (en) 2005-01-21 2010-12-21 The Research Foundation Of State University Of New York Method for treating lateral epicondylitis using collagenase
US20070224184A1 (en) 2006-02-22 2007-09-27 The Research Foundation Of The State University Of New York Method for treating cellulite
AU2006216544B2 (en) 2005-02-25 2012-04-05 Onconova Therapeutics, Inc. Unsaturated sulfides, sulfones, sulfoxides and sulfonamides synthesis
CA2612768A1 (en) 2005-06-30 2007-01-11 Mallinckrodt Inc. Dual chamber syringe
US20070128685A1 (en) 2005-07-01 2007-06-07 Rodolfo Faudoa Methods and compositions for cell culture
US20070004036A1 (en) 2005-07-01 2007-01-04 Rodolfo Faudoa Methods and compositions for keratinocyte culture
US20070003541A1 (en) 2005-07-01 2007-01-04 Rodolfo Faudoa Methods and compositions for therapeutics
US7811560B2 (en) 2006-01-30 2010-10-12 Auxilium Us Holdings, Llc Compositions and methods for treating collagen-mediated diseases
US20080131500A1 (en) 2006-12-04 2008-06-05 The Board Of Regents Of The University Of Texas System Methods and compositions for rapid inactivation of proteins
SI4269578T1 (sl) 2008-03-06 2024-07-31 Halozyme, Inc. Sestava topne hialuronidaze
TWI395593B (zh) 2008-03-06 2013-05-11 Halozyme Inc 可活化的基質降解酵素之活體內暫時性控制
KR20130116386A (ko) 2008-04-14 2013-10-23 할로자임, 아이엔씨 히알루로난 관련 질환 및 상태 치료용 변형된 히알루로니다제 및 그 용도
EA022752B1 (ru) 2008-12-09 2016-02-29 Галозим, Инк. Длинные растворимые полипептиды рн20 и их использование
EP2403523A1 (en) 2009-03-06 2012-01-11 Halozyme, Inc. Temperature sensitive mutants of matrix metalloprotease 1 und uses thereof
CN102369296A (zh) 2009-03-09 2012-03-07 生物蛋白有限公司 Mirac蛋白
MX349622B (es) 2010-09-08 2017-08-07 Halozyme Inc Metodos para evaluar e identificar o evolucionar proteinas terapeuticas condicionalmente activas.
AU2013229786B2 (en) 2012-03-08 2017-06-22 Halozyme, Inc. Conditionally active anti-epidermal growth factor receptor antibodies and methods of use thereof

Similar Documents

Publication Publication Date Title
JP2011517318A5 (https=)
AR076627A1 (es) Composicion. uso.combinacion. kit. control temporal in vivo de enzimas activables degradadoras de matriz. recipiente
Sabatini et al. Mechanisms regulating the degradation of dentin matrices by endogenous dentin proteases and their role in dental adhesion. A review
Abbenante et al. Protease inhibitors in the clinic
Itoh et al. Matrix metalloproteinases in cancer
Shankar et al. Protease enzymes: highlights on potential of proteases as therapeutics agents
Delaisse et al. A new synthetic inhibitor of mammalian tissue collagenase inhibits bone resorption in culture
Ohnishi et al. Effects of urinary trypsin inhibitor on pancreatic enzymes and experimental acute pancreatitis
Cudic et al. Extracellular proteases as targets for drug development
DE19834591A1 (de) Verfahren zur Steigerung des Blutglukosespiegels in Säugern
PH12015502306A1 (en) Matrix metalloproteinases and uses thereof
CA2389337A1 (en) Reversibly inactivated acidified plasmin
JP2016520550A5 (https=)
Longhi et al. The effects of host derived metalloproteinases on dentin bond and the role of MMPs inhibitors on dentin matrix degradation
JP2820699B2 (ja) 血栓溶解剤
US20070212358A1 (en) Compositions and Methods for Effecting Controlled Posterior Vitreous Detachment
Schmid et al. Protease-antiprotease interactions and the rationale for therapeutic protease inhibitors
Gu et al. Chemically modified tetracycline-3 (CMT-3): a novel inhibitor of the serine proteinase, elastase
Barrett et al. The unique nature of the interaction of α2-macroglobulin with proteinases
US20070259030A1 (en) Methods, systems and reagents for tendon and ligament therapy
Das et al. Insights into the Role of Matrix Metalloproteinases and Tissue Inhibitor of Metalloproteinases in Health and Disease
Watanabe et al. Suppression of Matrix Metalloproteinase-2 and-9 Mediated Invasivenessbreak by a Novel Matrix Metalloproteinase Inhibitor, BE16627B
Norga et al. Human gelatinase B, a marker enzyme in rheumatoid arthritis, is inhibited by D-penicillamine: anti-rheumatic activity by protease inhibition
CA2634045C (en) Protease compositions for the treatment of damaged tissue
Keck Site-specific therapeutic effects of protease inhibitors: effect of route of administration in experimental pancreatitis